Liu, Qi, Lingli Hou, Ying Zhao, Hongwei Yang, Zhengying Mo, and Fei Yu. 2023. “Comparative Efficacy & Safety of Buparlisib Plus Fulvestrant, Fulvestrant Plus Dalpiciclib, and Ribociclib Plus Letrozole for Postmenopausal, Hormone Receptor-Positive, and HER2-Negative Breast Cancer”. Clinics 78 (May): 100291. https://doi.org/10.1016/.